Neoadjuvant immune checkpoint blockade triggers persistent and systemic T <sub>reg</sub> activation which blunts therapeutic efficacy against metastatic spread of breast tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant immune checkpoint blockade triggers persistent and systemic T _reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors

Published:2023-04-13 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Blomberg Olga S.¹²³,Kos Kevin¹²³,Spagnuolo Lorenzo¹²,Isaeva Olga I.¹,Garner Hannah¹²,Wellenstein Max D.¹²³,Bakker Noor¹²³,Duits Danique E.M.¹²³,Kersten Kelly¹,Klarenbeek Sjoerd⁴,Hau Cheei-Sing¹²,Kaldenbach Daphne¹²,Raeven Elisabeth A.M.¹²,Vrijland Kim¹²,Kok Marleen¹⁵,de Visser Karin E.¹²³^ORCID

Affiliation:

1. Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

2. Oncode Institute, Utrecht, The Netherlands

3. Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands

4. Experimental Animal Pathology Facility, Netherlands Cancer Institute, Amsterdam, Netherlands

5. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands

Funder

Oncode Institute

KWF/Oncode consortium

NWO Oncology Graduate School Amsterdam Diamond Program

Swiss National Science Foundation

BMS-International Immuno-Oncology Network

F. Hoffmann-La Roche

Ministry of Health

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2201147

Reference80 articles.

1. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

2. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

3. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

4. Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!

5. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives;Signal Transduction and Targeted Therapy;2024-08-02

2. Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy;Cancer Cell;2024-06

3. The Tumor Immune Microenvironment in Breast Cancer Progression;Acta Oncologica;2024-05-23

4. Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models;Breast Cancer Research;2024-04-11

5. Clinical and translational attributes of immune-related adverse events;Nature Cancer;2024-02-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3